Among them, TIF1γ has the highest positive rate in dermatomyositis patients with underlying malignancy (Hida et al., 2016), with about 60% to 80% of positive TIF-1 patients harboring a malignancy (Trallero-Araguas et al., 2010). This evidence concerns the gene TRIM33 and dermatomyositis.